Moderate to severe infections caused by susceptible strains of microorganisms. Initial empiric therapy prior to identification of causative organisms in complicated intra-abdominal infections; complicated skin & skin structure infections including diabetic lower extremity & foot infections; community-acquired pneumonia; complicated UTI including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion & post-surgical gynecologic infections; bacterial septicemia. Surgical prophylaxis of site infections following elective colorectal surgery.
Patient ≥13 yr 1 g once daily, 3 mth to 12 yr 15 mg/kg bid. Max: 1 g/day. Administer by IV infusion over 30 min or IM for 3-14 days. AdultSurgical prophylaxis of site infections following elective colorectal surgery 1 g as single IV dose given 1 hr prior to surgical incision. Patients w/ advanced renal insufficiency(CrCl ≤30 mL/min/1.73 m2) 500 mg daily. Patients on hemodialysis 500 mg w/in 6 hr prior to hemodialysis w/ a supplementary dose of 150 mg following hemodialysis.
View Invanz overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to ertapenem Na, or other β-lactams. IM inj: Hypersensitivity to amide-type local anesth & in patients w/ severe shock or heart block.
History of hypersensitivity to penicillins, cephalosporins, other β-lactams & other allergens. Discontinue immediately if an allergic reaction occurs. Patients w/ CNS disorders (eg, brain lesions or history of seizures) &/or compromised renal function. Concomitant use w/ valproic acid/divalproex Na. Consider supplemental anticonvulsant therapy in patients receiving valproic acid or divalproex Na in which Invanz administration is necessary. May result in overgrowth of non-susceptible organisms upon prolonged use. Pseudomembranous colitis especially in patients who present w/ diarrhea. Caution in administering IM to avoid inadvertent inj into a blood vessel. Pregnancy & lactation. Infant <3 mth.
Sign Out
